(Lung Cancer) Durvalumab + Tremelimumab + Chemotherapy: POSEIDON Trial Results
(Lung Cancer) Durvalumab + Tremelimumab + Chemotherapy: POSEIDON Trial Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Durvalumab + Tremelimumab + Chemotherapy: POSEIDON Trial Results
- November 15, 2022
- 1 min read
On November 3, 2022, Melissa L. Johnson et al. from Sarah Cannon Research Institute published in the medical journal Journal of Clinical Oncology the efficacy and safety results of anti-PD-L1 antibody anti-PD-L1 antibody + anti-CTLA-4 antibody Tremelimumab + chemotherapy as first-line treatment for metastatic non-small cell lung cancer patients in the POSEIDON Phase III clinical trial.
The POSEIDON Phase III clinical trial was an international multi-center trial that randomized metastatic non-small cell lung cancer patients (N=1,013) in a 1:1:1 ratio into the anti-PD-L1 antibody + Tremelimumab + chemotherapy group, the anti-PD-L1 antibody + chemotherapy group, and the chemotherapy group. The primary endpoints were progression-free survival and overall survival for the anti-PD-L1 antibody + chemotherapy group, with secondary endpoints being progression-free survival and overall survival for the anti-PD-L1 antibody + Tremelimumab + chemotherapy group.
The trial results showed that the primary endpoint median progression-free survival for the anti-PD-L1 antibody + chemotherapy group was 5.5 months with a median overall survival of 13.3 months. The secondary endpoint median progression-free survival for the anti-PD-L1 antibody + Tremelimumab + chemotherapy group was 6.2 months with a median overall survival of 14.0 months.
Regarding safety, grade 3-4 adverse event rates were 51.8% for the anti-PD-L1 antibody + Tremelimumab + chemotherapy group, 44.6% for the anti-PD-L1 antibody + chemotherapy group, and 44.4% for the chemotherapy group. Treatment discontinuation due to adverse events occurred in 15.5% of the anti-PD-L1 antibody + Tremelimumab + chemotherapy group, 14.1% of the anti-PD-L1 antibody + chemotherapy group, and 9.9% of the chemotherapy group.
Based on the POSEIDON trial results, Melissa L. Johnson et al. stated that anti-PD-L1 antibody + Tremelimumab + chemotherapy as first-line treatment for metastatic non-small cell lung cancer patients showed improvement in progression-free survival and overall survival compared to chemotherapy alone. anti-PD-L1 antibody + chemotherapy also showed improved progression-free survival compared to chemotherapy, and anti-PD-L1 antibody may become a new first-line treatment option for metastatic non-small cell lung cancer.
Source: https://ascopubs.org/doi/full/10.1200/JCO.22.00975
-
Investigational Drugs
-
Immunotherapy
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.